全球前列腺癌诊断市场规模、份额、趋势和成长分析报告（2026-2034年）

预计摄护腺癌诊断市场将从 2025 年的 102.7 亿美元成长到 2034 年的 189.4 亿美元，2026 年至 2034 年的复合年增长率为 7.04%。

受前列腺癌发病率上升和人们对早期检测重要性认识不断提高的推动，前列腺癌诊断市场预计将显着增长。随着全球人口老化，前列腺癌的盛行率预计将继续上升，从而增加对有效诊断工具的需求。多参数磁振造影（MRI）和先进超音波等影像技术的创新正在提高前列腺癌检测和鑑别的准确性。此外，包括前列腺特异性抗原（PSA）检测和基因谱分析在内的基于生物标记的检测方法的发展，正在改变前列腺癌的诊断格局，并推动前列腺癌个人化治疗方案的发展。

技术进步也在塑造前列腺癌诊断市场的未来。将人工智慧 (AI) 和机器学习演算法整合到诊断影像中，提高了肿瘤检测和风险分层的准确性。这些技术可以分析大量数据，识别传统方法可能遗漏的模式和异常，最终实现更准确的诊断。此外，液态生物检体技术的兴起，为临床医生提供了一种非侵入性的疾病进展和治疗反应监测方法，进一步增强了其诊断能力。

此外，随着製药公司和诊断设备製造商认识到前列腺癌检测和治疗方面尚未满足的需求，加大研发投入将对前列腺癌诊断市场产生积极影响。学术机构、医疗服务提供者和产业相关人员之间的合作对于推动临床试验和将创新诊断解决方案推向市场至关重要。随着监管机构不断简化新技术核准流程，重点将转向将诊断技术整合到全面的前列腺癌治疗方案中。这种整合将凸显结合诊断见解和治疗计划的多方面方法的重要性，从而优化患者预后。随着大众对前列腺癌的认识不断提高，促进筛检和提高公众意识的公共卫生措施将进一步推动对先进诊断工具的需求，最终有助于提高患者的生存率和生活品质。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

第四章：全球前列腺癌诊断市场：依检测类型划分

• 市场分析、洞察与预测
• 初步检查
• 确认性检测

第五章 全球前列腺癌诊断市场：按类型划分

• 市场分析、洞察与预测
• 腺癌
• 间质细胞癌
• 其他的

第六章：全球前列腺癌诊断市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 门诊部
• 居家医疗
• 研究/製造

第七章 全球前列腺癌诊断市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • MDx Health
  • Myriad Genetics Inc
  • Abbott Laboratories
  • F. Hoffman-La Roche AG
  • Bayer AG
  • Siemens Healthcare GmbH
  • OPKO Health Inc
  • Genomic Health
  • Pfizer Inc

The Prostate Cancer Diagnostics Market size is expected to reach USD 18.94 Billion in 2034 from USD 10.27 Billion (2025) growing at a CAGR of 7.04% during 2026-2034.

The prostate cancer diagnostics market is poised for significant growth, driven by the increasing incidence of prostate cancer and the growing awareness of the importance of early detection. As the global population ages, the prevalence of prostate cancer is expected to rise, leading to a heightened demand for effective diagnostic tools. Innovations in imaging technologies, such as multiparametric MRI and advanced ultrasound techniques, are enhancing the accuracy of prostate cancer detection and characterization. Additionally, the development of biomarker-based tests, including prostate-specific antigen (PSA) testing and genetic profiling, is revolutionizing the diagnostic landscape, enabling personalized approaches to prostate cancer management.

Technological advancements are also shaping the future of the prostate cancer diagnostics market. The integration of artificial intelligence and machine learning algorithms into diagnostic imaging is improving the precision of tumor detection and risk stratification. These technologies can analyze vast amounts of data to identify patterns and anomalies that may be missed by traditional methods, ultimately leading to more accurate diagnoses. Furthermore, the rise of liquid biopsy techniques is providing a non-invasive alternative for monitoring disease progression and treatment response, further enhancing the diagnostic capabilities available to clinicians.

Moreover, the prostate cancer diagnostics market will benefit from increased investment in research and development, as pharmaceutical companies and diagnostic firms recognize the unmet needs in prostate cancer detection and management. Collaborative efforts between academic institutions, healthcare providers, and industry stakeholders will be crucial in advancing clinical trials and bringing innovative diagnostic solutions to market. As regulatory bodies continue to streamline approval processes for new technologies, the focus will shift towards integrating diagnostics into comprehensive prostate cancer care pathways. This integration will emphasize the importance of multidisciplinary approaches, combining diagnostic insights with treatment planning to optimize patient outcomes. As awareness of prostate cancer grows, public health initiatives aimed at promoting screening and education will further drive the demand for advanced diagnostic tools, ultimately contributing to improved survival rates and quality of life for patients.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Preliminary Tests
• Confirmatory Tests

By Type

• Adenocarcinoma
• Interstitial Cell Carcinoma
• Other

By End Use

• Hospitals
• Outpatient Facilities
• Home Care
• Research & Manufacturing

COMPANIES PROFILED

• MDx Health, Myriad Genetics Inc, Abbott Laboratories, F HoffmanLa Roche AG, Bayer AG, Siemens Healthcare GmbH, OPKO Health Inc, Genomic Health, Pfizer Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Preliminary Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Confirmatory Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Adenocarcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Interstitial Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Outpatient Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Research & Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROSTATE CANCER DIAGNOSTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 MDx Health
  • 9.2.2 Myriad Genetics Inc
  • 9.2.3 Abbott Laboratories
  • 9.2.4 F. Hoffman-La Roche AG
  • 9.2.5 Bayer AG
  • 9.2.6 Siemens Healthcare GmbH
  • 9.2.7 OPKO Health Inc
  • 9.2.8 Genomic Health
  • 9.2.9 Pfizer Inc